Katalysen portfolio company QuTEM marks growing recognition of core technology as USP includes CryoTEM in AAV reference standard certificates
Katalysen Ventures AB (publ) ("Katalysen") notes that Stockholm-based portfolio company QuTEM AB ("QuTEM"), in which Katalysen holds a 15% ownership stake through Venture Targeter, has announced that Cryogenic Transmission Electron Microscopy (“CryoTEM”) has been included as a new analytical method in updated certificates for the U.S. Pharmacopeia’s (“USP”) AAV8 reference standards. QuTEM is a pioneer in quantitative CryoTEM for biopharmaceutical applications and has spent years developing validated methodologies, automated workflows, and proprietary software solutions for CryoTEM-based